European Physician and Payer Perspective on Current Mainstays and Novel Entrants in the Age of Austerity Parkinson’s disease (PD) is a debilitating chronic neurodegenerative disease affecting…
For the estimated 2 million diagnosed patients in the United States who suffer from rheumatoid arthritis (RA), there are multiple prescription therapies that are available for treating the…
Physician Perspectives and the Impact of Payer Policy on Prescribing An estimated 121 million people are living with chronic kidney disease (CKD) in China. This high prevalence can be attributed…
How Are Payers Responding to High-Cost Therapies on Their Exchange-Based Plans? The Affordable Care Act (ACA) has expanded access to insurance coverage to millions and has reformed health insurance…
For the estimated 2.1 million people in the United States with rheumatoid arthritis (RA), there are multiple disease modifying anti-rheumatic drugs (DMARDs) available for reducing the signs and…
The entrenched positioning of biologics (in particular, tumor necrosis factor-alpha [TNF-alpha] inhibitors) to treat moderate to severe rheumatoid arthritis (RA) has generated a multibillion-dollar…
In 2013, painful diabetic neuropathy (PDN) affected more than 3.4 million people in the United States. Similar to postherpetic neuralgia, PDN has also served—and continues to serve—as a gateway…
Warfarin has been the mainstay of anticoagulation therapy for the past several decades, but difficulties associated with its use and the clinical management of patients have prompted the…
Treatment for breast cancer (CaB) in the United States has matured as oncologists have formalized protocols around specific patient populations, namely HER2+, HR+/HER2-, and HR-/HER2- (also known…